1. Draw 2 mL bacteriostatic water with a sterile syringe.
2. Inject slowly down the vial wall; avoid foaming.
3. Gently swirl until fully dissolved (do not shake).
4. Label with date and refrigerate at 2 to 8 °C, protected from light; use within 30 days. Reconstitution math: 5 mg cagrilintide + 5 mg Semaglutide = 10 mg total blend; 10 mg ÷ 3.0 mL = 5 mg/mL total. At 5 mg/mL, 1 unit = 0.01 mL » 50 mcg total (16.7 mcg each peptide).

Cagrilintide is a long-acting amylin analog that reduces appetite via central satiety pathways, while Semaglutide activates GLP-1 receptors to enhance glucose-dependent insulin secretion and suppress glucagon. The combination leverages complementary mechanisms: amylin primarily delays gastric emptying and signals satiety through the area postrema, while GLP-1 enhances pancreatic b-cell function and central appetite suppression. Clinical trials of the co-administered regimen (CagriSema) show greater body-weight reduction than either agent alone.

• Weight reduction: Phase 2 trials report mean body-weight loss of ~15 to 17% at 32 weeks with the
  combination, exceeding Semaglutide monotherapy.
• Glycemic control: In type 2 diabetes, HbA1c reductions were observed alongside weight loss.
  GI tolerability: Nausea, vomiting, and diarrhea are the most common adverse events; gradual titration minimizes severity.
• Injection-site reactions: mild and transient in clinical reports.